Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 359 participants.
Also called NCT04668144
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 359 participants
- Sponsor
- Registry
-
NCT04668144
-
- Other papers using this trial's data
- Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet-6 (SWAP-6) Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT04668144. Randomized; no masking; primary purpose treatment. Start 2021-02-18 (actual); primary completion 2023-02-02 (actual). Results posted on 2024-03-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI
- Acronym
- SWAP-6
- Condition
- Coronary Artery Disease
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- Cangrelor
- Intervention (Drug)
- Prasugrel
- Lead sponsor
- University of Florida
- Collaborator
- Scott R. MacKenzie Foundation
Record details
- Record id
cardio:ct-nct04668144- Content hash
1086b6989f9a3e3b54cfaefd1b123b85f88e33c2a7bcb4942db57eb48dd9ee22